SCHEMBL16184255

SCHEMBL16184255

Fc1cccc(-c2ccc3c(N4CC(F)(F)C4)nc(-c4cccnc4)nc3c2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.48
▸ LMNA P02545 3/20 0.48
▸ TSHR P16473 2/20 0.48
▸ MAPT P10636 2/20 0.48
▸ USP2 O75604 2/20 0.48
▸ MAPK1 P28482 1/20 0.48
▸ NPSR1 Q6W5P4 1/20 0.48
▸ HSD17B10 Q99714 1/20 0.48
▸ GBA1 P04062 8/20 0.47
▸ CYP1A2 P05177 3/20 0.47
▸ CYP3A4 P08684 3/20 0.47
▸ CLK4 Q9HAZ1 3/20 0.47
▸ CYP2D6 P10635 2/20 0.47
▸ ALOX15 P16050 2/20 0.47
▸ HTT P42858 1/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ ABCG2 Q9UNQ0 2/20 0.45
▸ PDE5A O76074 2/20 0.43
▸ GAA P10253 1/20 0.41
▸ MEN1 O00255 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16184262 0.94 ALDH1A1 (0.48) ALDH1A1LMNATSHRMAPTUSP2
SCHEMBL16184256 0.93 ALDH1A1 (0.49) ALDH1A1LMNATSHRMAPTUSP2
SCHEMBL16184253 0.90 LMNA (0.57) ALDH1A1LMNATSHRMAPTUSP2
SCHEMBL16184260 0.90 ALDH1A1 (0.48) ALDH1A1LMNATSHRMAPTUSP2
SCHEMBL16184258 0.88 ALDH1A1 (0.47) ALDH1A1LMNATSHRMAPTUSP2
SCHEMBL16184261 0.88 ALDH1A1 (0.45) ALDH1A1LMNATSHRMAPTUSP2
SCHEMBL16184245 0.87 TSHR (0.61) ALDH1A1LMNATSHRMAPTUSP2
SCHEMBL16184257 0.86 ALDH1A1 (0.45) ALDH1A1LMNATSHRMAPTUSP2
SCHEMBL16184254 0.86 ALDH1A1 (0.49) ALDH1A1LMNATSHRMAPTUSP2
SCHEMBL16184161 0.84 ALDH1A1 (0.51) ALDH1A1LMNATSHRMAPTUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE PPP2CA, PPP4C, PPP3CB ALDH1A1 1687/4885LMNA 4832/4885TSHR 2280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback